ArticleScientific reports2026
Influenza A virus derived NS1 enhances translation of HPLC purified mRNA and interferon adjuvanted mRNA vaccination.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Growth ofBiomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-structural protein (NS1) derived from influenza A virus is a potent immune evasion protein capable of enhancing translation of nucleoside-modified mRNA via host gene expression inhibition (HGEI) effect. In this study, we show that the HGEI effect on NS1 transfected cells reduces de novo synthesis and polyadenylation of host RNA. Co-delivering NS1 mRNA also enhances translation of non-inflammatory nucleoside-modified and HPLC-purified mRNA in NIH3T3 cells. Co-delivering NS1 mRNA also enhances translation of nucleoside-modified mRNA in DCs by 100% based on GFP expression, but completely inhibits cytokine induced maturation of primary human dendritic cells (DCs). Co-delivering NS1 mRNA also significantly enhances in vivo translation of naked mRNA via intramuscular route with transgene expression persisting for 12 days. As a proof of concept to mimic natural viral infection, when mRNAs encoding NS1 and interferon alpha were co-delivered, translation inhibition of the reporter gene was rescued both in vitro and in vivo. Using ovalbumin as a model antigen, we show that humoral response in C57BL/6 mice was enhanced when naked mRNAs encoding ovalbumin, NS1 and IFN were delivered together via intramuscular route. These novel properties of NS1 have the potential to impact mRNA therapeutics in significant ways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.